Botulinum Toxin in Pain Treatment

Dressler, 2005, Botulinum toxin: mechanisms of action, Arq Neuropsiquiatr, 63, 180, 10.1590/S0004-282X2005000100035

Lang, 2004, History and uses of BOTOX (botulinum toxin type A), Lippincott's Case Manag, 9, 109, 10.1097/00129234-200403000-00011

Wenzel, 2004, Pharmacology of botulinum neurotoxin serotype A, Am J Heath-Syst Pharm, 61, s5, 10.1093/ajhp/61.suppl_6.S5

Setler, 2002, Therapeutic use of botulinum toxins: background and history, Clin J Pain, 18, s119, 10.1097/00002508-200211001-00002

Aguilar-Rebolledo, 2001, Toxina botulínica como tratamiento de la espasticidad y distonia en la parálisis cerebral infantil, Gac Méd Mex, 137, 403

Wohlfarth, 2004, Pharmacokinetic properties of different formulations of botulinum neurotoxin type A, Mov Disord, 19, s65, 10.1002/mds.20012

Aoki, 2005, Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A, Neurotoxicology, 26, 785, 10.1016/j.neuro.2005.01.017

Freund, 2003, Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A, J Pain, 4, 159, 10.1054/jpai.2003.435

Aoki, 2001, Pharmacology and immunology of botulinum toxin serotypes, J Neurol, 248, 3, 10.1007/PL00007816

Mejia, 2005, Long-term botulinum toxin efficacy, safety and immunogenicity, Mov Disord, 20, 592, 10.1002/mds.20376

Graboski, 2005, Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study, Pain, 118, 170, 10.1016/j.pain.2005.08.012

Sycha, 2006, A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model, Anesth Analg, 102, 509, 10.1213/01.ane.0000194447.46763.73

Sheeran, 2002, Botulinum toxin for the treatment of musculoskeletal pain and spasm, Curr Pain Headache Rep, 6, 460, 10.1007/s11916-002-0065-y

Lew, 2002, Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction, Clin J Pain, 18, s142, 10.1097/00002508-200211001-00005

Klein, 2004, The therapeutic potential of botulinum toxin, Dermatol Surg, 30, 452

Porta, 1998, The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A, Pain Digest, 8, 346

Kamanli, 2005, Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome, Rheumatol Int, 25, 604, 10.1007/s00296-004-0485-6

von Lindern, 2003, Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity, J Oral Maxillofac Surg, 61, 774, 10.1016/S0278-2391(03)00153-8

Jabbari, 2006, Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an openlabel, pilot study, Pain Med, 7, 260, 10.1111/j.1526-4637.2006.00147.x

Silberstein, 2006, Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study, Cephalalgia, 26, 790, 10.1111/j.1468-2982.2006.01114.x

Smuts, 2004, Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study, Headache, 44, 801, 10.1111/j.1526-4610.2004.04148.x

Allen, 1999, Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients, Pain, 80, 539, 10.1016/S0304-3959(98)00246-2

Lang, 2003, Botulinum toxin type A therapy in chronic pain disorders, Arch Phys Med Rehabil, 84, s69, 10.1053/apmr.2003.50121